Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

Leukemia. 2015 Mar;29(3):744-7. doi: 10.1038/leu.2014.308. Epub 2014 Oct 28.

Authors

C Pepper¹, A G S Buggins², C H Jones¹, E J Walsby¹, F Forconi³, G Pratt⁴, S Devereux², F K Stevenson³, C Fegan¹

Affiliations

¹ Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
² Department of Haematology, King's College London, London, UK.
³ Cancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK.
⁴ CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use*
Benzylamines
Chemokine CXCL12 / genetics
Chemokine CXCL12 / metabolism
Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases / genetics
Class I Phosphatidylinositol 3-Kinases / metabolism
Cyclams
Gene Expression Regulation, Neoplastic*
Genetic Heterogeneity
Heterocyclic Compounds / therapeutic use
Humans
Immunoglobulin Heavy Chains / genetics*
Immunoglobulin Heavy Chains / metabolism
Integrin alpha4 / genetics*
Integrin alpha4 / metabolism
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Mutation
Natalizumab
Piperidines
Prognosis
Protein-Tyrosine Kinases / antagonists & inhibitors
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Purines / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Quinazolinones / therapeutic use
Receptors, CXCR4 / antagonists & inhibitors
Receptors, CXCR4 / genetics*
Receptors, CXCR4 / metabolism
Signal Transduction
Survival Analysis

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Benzylamines
CXCL12 protein, human
CXCR4 protein, human
Chemokine CXCL12
Cyclams
Heterocyclic Compounds
Immunoglobulin Heavy Chains
Natalizumab
Piperidines
Purines
Pyrazoles
Pyrimidines
Quinazolinones
Receptors, CXCR4
Integrin alpha4
ibrutinib
Class I Phosphatidylinositol 3-Kinases
PIK3CD protein, human
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human
Adenine
plerixafor
idelalisib